New platelet blocker reduces blood clots, artery-opening procedures
June 20, 2012
Study Highlights:
- An investigational platelet-blocking drug reduced the rate of dangerous blood clots in the legs and the need for artery-opening surgery in people with peripheral artery disease.
- However, the drug didn’t significantly reduce the risk of heart attack or stroke, and those taking the blood thinner had higher rates of serious bleeding incidents.
- The research is part of the American Heart Association’s Emerging Science Series, a free online webinar presentation. View the webinar at www.scientificsessions.org/emergingscience
.
EMBARGOED UNTIL Noon CT/1 pm ET, Wednesday, June 20, 2012
DALLAS, June 20, 2012 — A new investigational platelet blocker reduces the rate of clotted arteries and the need for artery-opening revascularization procedures in the legs in people with peripheral artery disease (PAD), according to new research presented in the American Heart Association’s Emerging Science Series webinar.
(PAD), according to new research presented in the American Heart Association’s Emerging Science Series webinar.“Much of the focus on PAD therapies has been on lowering patients’ risk of heart attack and stroke, but this shows that there can be therapies that reduce limb-threatening blood clots and the need for revascularization procedures in the legs,” said Marc P. Bonaca, M.D., M.P.H., Instructor of medicine at Harvard Medical School and Brigham and Women’s Hospital in Boston, Mass., and an investigator with the Thrombolysis in Myocardial Infarction (TIMI) study group.
In the study, researchers randomized 3,787 patients with PAD to receive standard care or standard care plus vorapaxar, the first in a new class of anti-platelet drugs called PAR-1 antagonists. Participants were part of the 26,449-patient TRA2P-TIMI 50 trial testing 2.5 milligrams per day (mg/day) of vorapaxar in people with a history of heart attack, stroke or PAD. The TRA2P-TIMI 50 trial main results presented earlier this year showed a statistically significant reduction in cardiovascular events including heart attack, stroke, and cardiovascular death with vorapaxar. In this substudy focused on participants with PAD, 11.3 percent of those taking vorapaxar experienced these major cardiovascular events compared with 11.9 percent of those taking a placebo – a numeric reduction consistent with the overall trial findings that did not reach statistical significance on its own. However, they found benefits of vorapaxar on limb events. Compared to those not receiving the drug:
- Fewer vorapaxar patients were hospitalized for blood clots in the limbs (2.3 percent vs. 3.9 percent).
- Fewer vorapaxar patients required revascularization to restore full blood flow in narrowed or blocked vessels in the limbs (18.4 percent vs. 22.2 percent).
“This is the first outpatient therapy that has been shown to reduce the risk of blood clots and the need for artery opening revascularization procedures in the legs in patients with PAD,” Bonaca said. The reduction in both urgent blood clots as well as the need for surgery to treat worsening atherosclerosis suggests that the drug may be working in more than one way. “The target for this therapy is expressed on platelets but also on cells in the artery walls that are important for normal artery function. The benefits observed may be due to drug activity at both sites,” noted Bonaca.
Moderate and severe bleeding was increased in patients on vorapaxar compared to those on standard care (7.4 percent vs. 4.5 percent consistent with the overall trial); however, there was no increase in fatal bleeding. “For clinicians and researchers, these data show the potential for therapies that can reduce leg problems in patients with PAD rather than just overall cardiovascular risk,” Bonaca said.
The investigators are analyzing whether vorapaxar treatment improves circulation in the lower body, or allows patients to walk further without pain due to insufficient blood flow to leg muscles (claudication). All of the PAD patients in the study initially had symptoms of claudication, and either poor leg circulation or a previous vessel-opening procedure.
Co-authors are David A. Morrow, M.D., M.P.H., and Eugene Braunwald, M.D.
Merck funded the study.
For more information on peripheral artery disease, visit www.heart.org/pad .
.###
Statements and conclusions of study authors published in American Heart Association scientific journals or presented at American Heart Association conferences are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding .
.NR12 –1088 (ESS/Bonaca)
Additional resources available on the right column of this link:
For media inquiries: (214) 706-1173
Maggie Francis: (214) 706-1382; maggie.francis@heart.org
Carrie Thacker: (214) 706-1665; carrie.thacker@heart.org
Julie Del Barto (broadcast): (214) 706-1330; julie.delbarto@heart.org
For public inquiries: (800) AHA-USA1 (242-8721)
.png)
No hay comentarios:
Publicar un comentario